… Members of the C-EDGE CO-STAR Study Group who authored this work: Gregory J. Dore,
MD (The Kirby Institute, UNSW Australia, Sydney, Australia); Frederick Altice, MD (Yale …

Background. Coinfection with human immunodeficiency virus type 1 (HIV-1) increases the
risk of hepatitis B virus (HBV)-associated progressive liver disease. Lamivudine has potent …

Hepatitis C virus (HCV) infects 3% of the world's population. Treatment of chronic HCV consists
of a combination of PEGylated interferon-α (PEG-IFN-α) and ribavirin (RBV). To identify …

A proportion of patients surviving acute coronavirus disease 2019 (COVID-19) infection develop
post-acute COVID syndrome (long COVID (LC)) lasting longer than 12 weeks. Here, we …

Background The 69th World Health Assembly approved the Global Health Sector Strategy
to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the …

Objectives: To determine the protective efficacy of highly active antiretroviral therapy (HAART)
against AIDS dementia complex (ADC) relative to other initial AIDS-defining illnesses (…

To gain a clearer understanding of the rate of progression to cirrhosis and its determinants
in chronic hepatitis C virus (HCV) infection, a systematic review of published epidemiologic …

Objective: To determine the effect of introduction of highly active antiretroviral therapy (HAART)
on survival following AIDS dementia complex (ADC). Methods: Australian AIDS …

Worldwide, an estimated 130–170 million people have HCV infection. HCV prevalence is
highest in Egypt at >10% of the general population and China has the most people with HCV (…

Published estimates of liver fibrosis progression in individuals with chronic hepatitis C virus (HCV)
infection are heterogeneous. We aimed to estimate stage‐specific fibrosis …